Leerink Partners Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 92.9%

Neg 92.9% Neu 0% Pos 0%

Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $39 to $27.